The nonbiologic DMARD leflunomide was approved for use in the treatment of rheumatoid arthritis in 1998. After being in use for more than a decade, which has also seen the introduction of highly effective biologic agents, a review of the benefits and risks of leflunomide therapy sheds light on the role of this drug in the treatment arsenal.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Alcorn, N., Saunders, S. & Madhok, R. Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf. 32, 1123–1134 (2009).
Poór, G. et al. Efficacy and safety of leflunomide 10 mg vs 20 mg once daily in patients with active rheumatoid arthritis: multinational double-blind, randomized trial. Rheumatology (Oxford) 43, 744–749 (2004).
Jakez-Ocampo, J., Richaud-Patin, Y., Simón, J. A. & Llorente, L. Weekly dose of leflunomide for the treatment of refractory rheumatoid arthritis: an open pilot comparative study. Joint Bone Spine 69, 307–311 (2002).
Osiri, M. et al. Leflunomide for the treatment of rheumatoid arthritis. Cochrane Database of Systematic Reviews 2002, Issue 3. Art. No.: CD002047 (2002). doi:10.1002/14651858.CD002047.
Finckh, A., Dehler, S. & Gabay, C. The effectiveness of leflunomide as co-therapy of TNF inhibitors in rheumatoid arthritis: a population-based study. Ann. Rheum. Dis. 68, 33–39 (2009).
Strangfeld, A. et al. Comparative effectiveness of tumour necrosis factor α inhibitors in combination with either methotrexate or leflunomide. Ann. Rheum. Dis. 68, 1856–1862 (2009).
De Stefano, R. et al. Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha. Clin. Rheumatol. 29, 517–524 (2010).
Bingham, S. J., Buch, M. H., Kerr, M. A., Emery, P. & Valadäo Barcelos, A. T. Induction of antinuclear antibodies in patients with rheumatoid arthritis treated with infliximab and leflunomide. Arthritis Rheum. 50, 4072–4073 (2004).
Chambers, C. D. et al. Birth outcomes in pregnant women taking leflunomide. Arthritis Rheum. doi:10.1002/art.27358.
Goekoop-Ruiterman, Y. P. et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 52, 3381–3390 (2005).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Osiri, M. Is there a place for leflunomide in the treatment of RA?. Nat Rev Rheumatol 6, 387–389 (2010). https://doi.org/10.1038/nrrheum.2010.76
Issue date:
DOI: https://doi.org/10.1038/nrrheum.2010.76
